Regenxbio RGNX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -292.3%-192pp | -94.6%+185pp | -96%+196pp | -105.7%+174pp | -100.4%+206pp | |
| Net margin | -330.2%-230pp | -113.8%+159pp | -110.3%+173pp | -112.7%+158pp | -100.6%+199pp | |
| EBITDA margin | -274.6%-184pp | -85.4%+175pp | -86.3%+186pp | -95.5%+165pp | -90.2%+196pp | |
| Free cash flow margin | -269.2%-214pp | -74.1%+137pp | -65.9%+153pp | -58.2%+160pp | -55.5%+174pp | |
| Returns | ||||||
| Return on equity | -196.4%-149pp | -107%-27.5pp | -76.9%-5.0pp | -62.5%+1.4pp | -47.4%+13.4pp | |
| Return on assets | -69.6%-41.5pp | -42.2%+1.5pp | -34.1%+7.4pp | -30.5%+8.0pp | -28.2%+9.6pp | |
| Return on invested capital | -170.6%-117pp | -75.7%-4.0pp | -61%+6.4pp | -56%+5.8pp | -53.4%+8.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.4×+0.2× | 0.3×+0.2× | 0.3×+0.1× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 2.6×-0.3× | 2.4×-0.3× | 2.7×-0.4× | 3.1×-0.4× | 2.9×-0.7× | |
| Quick ratio | 2.6×-0.3× | 2.4×-0.3× | 2.7×-0.4× | 3.1×-0.4× | 2.9×-0.7× | |
| Cash ratio | 0.2×-1.0× | 0.3×-0.3× | 0.5×-0.1× | 0.7×+0.1× | 1.2×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 3.4×+3.1× | 0.7×+0.4× | 0.5×+0.2× | 0.4×+0.1× | 0.3×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Interest coverage | -5.7×+2.5× | -3.6×+14.9× | -3.7×+49.7× | -5.5×+40.5× | -8.2×+35.6× | |
| Per Share | ||||||
| Book value per share | $0.40-92.5% | $1.99-62.0% | $3.12-47.4% | $4.15-39.7% | $5.33-37.6% | |
| Valuation | ||||||
| Market capitalization | $529.38M+24.6% | $728.97M+90.3% | $487.46M-8.2% | $431.33M-19.4% | $358.12M-61.4% | |
| Enterprise value | $585.22M+56.3% | $768.01M+88.5% | $505.17M-9.5% | $429.47M-23.7% | $307.86M-65.8% | |
| Price / sales | 6×+3.3× | 4.3×-0.3× | 3×-3.3× | 2.8×-3.2× | 2.3×-8.4× | |
| Price / book | 25.1×+23.6× | 7.1×+5.6× | 3×+1.3× | 2×+0.5× | 1.3×-1.1× | |
| EV / sales | 6.7×+4.3× | 4.5×-0.4× | 3.1×-3.5× | 2.8×-3.6× | 2×-8.4× | |
| Free cash flow yield | -44.7%-24.2pp | -17.3%+28.5pp | -21.8%+13.0pp | -21%+15.4pp | -24.3%-2.9pp | |
| Earnings yield | -54.8%-17.7pp | -26.6%+32.7pp | -36.5%+8.5pp | -40.7%+4.3pp | -44%-16.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regenxbio's profit margins?
- Regenxbio (RGNX) runs a 59.7% gross margin and a -292.3% operating margin, with a -330.2% net margin.
- Where do Regenxbio's ratios come from?
- Every ratio is computed from Regenxbio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
